Adaptilens' CEO, Liane Clamen, joined an esteemed panel of CEOs to lead the MedTech CEO-Only Forum at #JPM25, hosted by Giovanni Lauricella, CEO of Lifeblood and Martin Gomez, Partner at Goodwin.

As we reflect on 2024, we're proud to spotlight over 130 remarkable achievements from our entrepreneurial community, driving innovation and impact across industries: • Adaptilens is developing an intraocular lens that responds to the eye's natural signal to focus, eliminating the need for eyeglasses or contact lenses. This year, the company raised $17.5 million in funding. • Akouos, a biotech company focused on restoring hearing in deaf children, was featured in The New York Times for helping a child hear for the first time. • IAMBIC is disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. In 2024, IAMBIC completed Techstars NYC, secured $1.25 million in non-dilutive federal and state funding, and expanded the team with seven key hires. Explore more inspiring accomplishments: https://lnkd.in/duWGZ5Kt

Adaptilens was well represented at the Ophthalmology Innovation Source XIV in San Diego where our CEO Liane Clamen spoke on the panel "Future of Anterior Innovation: A Panel of Disruptors and Visionaries." Thank you Anthony Wallace - Bausch + Lomb Surgical for inviting our CEO and facilitating an inspiring discussion.

Adaptilens is excited to share Rowan Walrath's well-researched and insightful article in C&EN showcasing successful founder-led biotech companies like Adaptilens. We appreciate Rowan's recognition of Adaptilens's Founder and CEO Liane Clamen and Rowan's spotlight on champions of the founder-led movement like Chris Garabedian, Gianna Hoffman-Luca, and their team at Xontogeny and Perceptive Advisors, as well as Tony Kulesa and the Pillar VC team.

Adaptilens is pleased to announce that our CEO, Dr. Liane Clamen, was invited to participate in a panel discussion on the "Future of Anterior Innovation" at the Ophthalmology Innovation Summit next month.